Physician profile
Amrit Thandi
NPI 1295771137
$3,383.36
in general payments reported to CMS, 2019-2025
17 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $392 · 2021: $783 · 2022: $336 · 2023: $300 · 2024: $529 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,341.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $582.17 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $359.22 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $318.53 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $191.76 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.88 | 2019-2021 | |
| Pfizer INC. | $114.74 | 2019-2024 | |
| Amgen INC. | $85.02 | 2020-2025 | Repatha, Krystexxa |
| Shield Therapeutics INC | $76.63 | 2022-2024 | Accrufer |
| Valeritas, INC. | $46.18 | 2019 | |
| Exact Sciences Corporation | $34.67 | 2025 | The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.04 | 2025 | Caplyta |
| Abbott Laboratories | $18.67 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.86 | 2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $14.39 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.03 | 2020 | |
| Allergan, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrit Thandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.